API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
EU WC
Listed Suppliers
0
USA (Orange Book)
0
Europe
Canada
0
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
0
Details:
UK MHRA approved Exblifep (cefepime/enmetazobactam) antibiotic which is indicated to treat adults suffering from complicated urinary tract infections (UTIs) and certain kinds of pneumonia acquired during hospital stays.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2024
Details:
The net proceeds will be used to fund the clinical trial for WCK 5222, a combination of cefepime and the novel β-lactam enhancer (BLE) zidebactam, currently being studied in a global Phase 3 trial in complicated urinary tract infection.
Lead Product(s): Cefepime,Zidebactam
Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 5222
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: ICICI Prudential
Deal Size: $57.5 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 28, 2024
Details:
Exblifep (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria. It is indicated for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, in patients 18 years and older.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
Details:
VNRX-5022 (cefepime) & taniborbactam combination is an investigational IV beta-lactam/beta-lactamase inhibitor antibiotic, being developed for treatment of complicated urinary tract infections, including pyelonephritis & bacterial pneumonia (HABP/VABP) in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5022
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2024
Details:
Menarini will acquire rights to commercialize, upon approval, VNRX-5022/VNRX-5133 (cefepime-taniborbactam), an investigational IV beta-lactam/beta-lactamase inhibitor antibiotic combination for complicated urinary tract infections, in 96 countries.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5022
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 09, 2024
Details:
The agreement aims to commercialize cefepime-taniborbactam, a beta-lactam inhibitor combination antibiotic being developed for the treatment of complicated UTI and hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: VenatoRx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2023
Details:
Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor antibiotic being developed by Venatorx Pharmaceuticals for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 19, 2023
Details:
Cefepime-taniborbactam is an investigational intravenous (IV) beta-lactam/beta-lactamase inhibitor (BL/BLI) antibiotic combination being developed for the treatment of complicated urinary tract infections.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2023
Details:
EXBLIFEP (cefepime/enmetazobactam) has been designed to combat anti-microbial resistance in gram-negative bacteria, especially resistance mediated by Extended Spectrum Beta Lactamases and which is investigated in patients with complicated urinary tract infections.
Lead Product(s): Cefepime,Enmetazobactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Exblifep
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
SYN-004 (ribaxamase) is designed to degrade certain IV beta-lactam antibiotics within the GI tract and maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms and aGVHD in allogeneic HCT recipients.
Lead Product(s): Ribaxamase,Cefepime
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2023
Details:
VNRX-5133 (cefepime), a fourth-generation cephalosporin, is a widely used beta-lactam (BL) antibiotic with more than two decades of proven safety and clinical utility against susceptible gram-negative and gram-positive bacteria.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
Among patients with cUTI caused by gram-negative pathogens, cefepime/enmetazobactam, compared with piperacillin/tazobactam, met criteria for noninferiority as well as superiority with respect to the primary outcome of clinical cure and microbiological eradication.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: AAI101
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
SYN-004 (ribaxamase) is an oral prophylactic therapy designed to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms, the emergence of AMR and aGVHD in allogeneic HCT recipients.
Lead Product(s): Ribaxamase,Cefepime
Therapeutic Area: Immunology Product Name: SYN-004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2022
Details:
Proceeds from financing will be used to support Venatorx as it advances its novel antibacterial VNRX-5133, through drug development process, including NDA with the U.S. FDA for cefepime-taniborbactam for the treatment of complicated urinary tract infections in adult patients.
Lead Product(s): Taniborbactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: VNRX-5133
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: AMR Action Fund
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series C Financing April 04, 2022
Details:
Cefepime-taniborbactam met primary efficacy endpoint of statistical non-inferiority to meropenem in microbiological intent-to-treat population in 70.0% of cefepime-taniborbactam treated patients and 58.0% of meropenem treated patients.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Everest Medicines
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 10, 2022
Details:
In a 7-day HFIM with humanized exposures and high initial inoculums, Cefepime (FEP)-Taniborbactam (TAN) provided sustained bactericidal activity against multidrug-resistant Enterobacterales and P. aeruginosa strains and suppressed growth of resistant subpopulations.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2020
Details:
Venatorx has granted GARDP exclusive rights to distribute and sub-distribute cefepime-taniborbactam, once it is approved for clinical use, in most low- and lower middle-income countries.
Lead Product(s): Cefepime,Taniborbactam
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: GARDP
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 28, 2020
Details:
EXBLIFEP demonstrated superiority in the primary endpoint of clinical cure and microbiological eradication at test-of-cure over piperacillin-tazobactam.
Lead Product(s): Enmetazobactam,Cefepime
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020